Related Experiment Videos
Azapropazone binding to human serum albumin
Naunyn-Schmiedeberg'S Archives of Pharmacology
|August 1, 1980
Summary
Azapropazone, a non-steroidal anti-inflammatory drug, binds strongly to human serum albumin at one high-affinity site and two low-affinity sites. Disease states affect binding due to sensitivity to inhibitors.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Metabolism
Background:
- Azapropazone is a non-steroidal anti-inflammatory drug (NSAID).
- NSAIDs exhibit strong binding to plasma proteins like human serum albumin (HSA).
- Understanding drug-protein interactions is crucial for predicting drug efficacy and disposition.
Purpose of the Study:
- To characterize the binding of azapropazone to human serum albumin.
- To investigate the potential overlap between azapropazone and other drug binding sites on HSA.
- To explore the influence of disease states on azapropazone-HSA binding.
Main Methods:
- Scatchard analysis to determine binding site stoichiometry and affinity.
- Optical measurements (e.g., fluorescence, circular dichroism) to probe conformational changes.
- Drug displacement studies to assess binding site competition.
Main Results:
- Azapropazone binds to HSA with one high-affinity site (Ka ≈ 1.2 x 10^6 M⁻¹) and two low-affinity sites (Ka ≈ 0.05 x 10^6 M⁻¹).
- The high-affinity site is distinct from diazepam and digitoxin binding sites.
- Evidence suggests azapropazone and warfarin may bind to overlapping but distinct regions on the same HSA site.
- Azapropazone binding is highly sensitive to endogenous inhibitors present during disease states.
Conclusions:
- Azapropazone exhibits complex binding kinetics to human serum albumin.
- The binding site for azapropazone is not identical to some other drug binding sites, but shows potential overlap with warfarin.
- Altered azapropazone plasma protein binding in disease states is attributed to heightened sensitivity to endogenous inhibitors rather than an unusual binding site.